Short Interest in Assembly Biosciences, Inc. (NASDAQ:ASMB) Declines By 12.0%

Assembly Biosciences, Inc. (NASDAQ:ASMB) was the recipient of a significant decrease in short interest in June. As of June 15th, there was short interest totalling 16,100 shares, a decrease of 12.0% from the May 31st total of 18,300 shares. Based on an average daily trading volume, of 18,600 shares, the days-to-cover ratio is presently 0.9 days. Currently, 0.4% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. StockNews.com raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Friday, May 10th. HC Wainwright restated a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, June 20th.

Assembly Biosciences Stock Performance

NASDAQ:ASMB opened at $12.49 on Wednesday. Assembly Biosciences has a 12-month low of $7.69 and a 12-month high of $20.04. The business has a 50 day simple moving average of $14.37 and a 200 day simple moving average of $12.72.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($1.66) EPS for the quarter, topping the consensus estimate of ($2.74) by $1.08. The firm had revenue of $5.79 million for the quarter. On average, equities research analysts predict that Assembly Biosciences will post -12.65 EPS for the current year.

Insider Buying and Selling at Assembly Biosciences

In other news, Director John G. Mchutchison sold 2,117 shares of Assembly Biosciences stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $14.93, for a total value of $31,606.81. Following the completion of the transaction, the director now owns 19,104 shares in the company, valued at approximately $285,222.72. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Insiders have sold 5,514 shares of company stock worth $76,055 over the last quarter. 5.10% of the stock is owned by corporate insiders.

Institutional Trading of Assembly Biosciences

A hedge fund recently bought a new stake in Assembly Biosciences stock. Marquette Asset Management LLC purchased a new stake in shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 54,464 shares of the biopharmaceutical company’s stock, valued at approximately $45,000. Marquette Asset Management LLC owned 0.08% of Assembly Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 19.92% of the company’s stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.